ImmuCell director granted 10,000 stock options

ImmuCell Corp. director Gloria F. Basse received a grant of 10,000 non-qualified stock options on Common Stock.

Rhea-AI Filing Summary

ImmuCell Corp. director Gloria F. Basse received a grant of 10,000 non-qualified stock options on Common Stock. These options were awarded as compensation at an exercise price of $5.49 per share, allowing her to buy up to 10,000 shares at that price if she chooses to exercise.

After this award, she holds options on 10,000 shares in total, with the options scheduled to become exercisable on April 16, 2028 and expiring on April 16, 2030. This is a routine equity incentive grant rather than an open-market stock purchase or sale.

Insider Trade Summary

Grant/Award: 10,000 shares

Grant/Award 1 txn

Insider Basse Gloria F

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Non Qualified Stock Options (Right to buy)	10,000	$0.00	$0.00

Holdings After Transaction: Non Qualified Stock Options (Right to buy) — 10,000 contracts (Direct)

Key Figures

Options granted: 10,000 options Exercise price: $5.49 per share Options exercisable date: April 16, 2028 +2 more

5 metrics

Options granted 10,000 options Non-qualified stock options granted on Common Stock

Exercise price $5.49 per share Strike price for 10,000 stock options

Options exercisable date April 16, 2028 Scheduled exercise date for granted options

Options expiration date April 16, 2030 Expiration date for granted options

Total options after grant 10,000 options Total derivative holdings following transaction

Key Terms

Non Qualified Stock Options, Grant, award, or other acquisition, underlying security

3 terms

Non Qualified Stock Options financial

"security_title: "Non Qualified Stock Options (Right to buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

underlying security financial

"underlying_security_title: "Common Stock""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ImmuCell (ICCC) report for Gloria F. Basse?

ImmuCell reported that director Gloria F. Basse received a grant of 10,000 non-qualified stock options. These options give her the right to buy 10,000 shares of Common Stock at a fixed exercise price as part of her equity-based compensation.

What is the exercise price of Gloria F. Basse’s new ImmuCell (ICCC) stock options?

The exercise price for Gloria F. Basse’s 10,000 non-qualified stock options is $5.49 per share. This means she can later purchase ImmuCell Common Stock at $5.49, regardless of the market price then, if she exercises the options.

When do Gloria F. Basse’s ImmuCell (ICCC) stock options become exercisable and when do they expire?

The options become exercisable on April 16, 2028 and expire on April 16, 2030. Between those dates, she can choose to exercise the options to buy ImmuCell Common Stock at the fixed $5.49 per share exercise price.

How many ImmuCell (ICCC) options does Gloria F. Basse hold after this Form 4 filing?

Following this transaction, Gloria F. Basse holds options on 10,000 shares of ImmuCell Common Stock. These are represented by the newly granted non-qualified stock options, with no additional derivative positions reported in this filing.

Was this ImmuCell (ICCC) Form 4 transaction an open-market buy or sell of shares?

No, this Form 4 reports a grant of non-qualified stock options, not an open-market share purchase or sale. It reflects an equity compensation award, giving the director future rights to buy shares at a fixed exercise price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/14/2026 - 03:34 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Basse Gloria F

(Last) (First) (Middle)

C/O IMMUCELL CORPORATION

56 EVERGREEN DRIVE

(Street)

PORTLAND MAINE 04103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IMMUCELL CORP /DE/ [ ICCC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/16/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non Qualified Stock Options (Right to buy)	$5.49	04/16/2025		A		10,000		04/16/2028	04/16/2030	Common Stock	10,000	$0	10,000	D

Explanation of Responses:

Remarks:

The options were granted by the Issuer to compensate directors for services on the Issuer's board of directors.

	/s/ Timothy C. Fiori Attorney-in-Fact	04/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)